This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celldex Announces Upcoming Data Presentations At The Society For Neuro-Oncology 17th Annual Scientific Meeting And Education Day

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced upcoming data presentations at the Society of Neuro-Oncology’s 17 th Annual Scientific Meeting and Education Day to be held in Washington, DC from November 15 through November 19, 2012. Duane A. Mitchell, MD, PhD, Assistant Professor of Surgery (Neurosurgery), Duke University Medical Center will present updated overall survival data from the rindopepimut Phase 2 ACT III, ACT II and ACTIVATE studies in an educational session entitled “Immunotherapy of Malignant Brain Tumors” to be held from 11:10-11:30 am ET on Thursday, November 15, 2012. Michael Weller, MD, Professor, Department of Neurology, University Hospital Zurich will present data from a cohort of patients with EGFRvIII-positive glioblastoma that were included in the Phase 3 Radiation Therapy Oncology Group’s (RTOG) 0525 study (closed to accrual in 2008) in an educational session called “Biomarkers and Clinical Care: are we there yet?” to be held from 5:05 to 5:25 pm ET on Thursday, November 15, 2012. This analysis will provide a more contemporary historical control dataset on expected outcomes for patients with EGFRvIII-positive disease.

Rindopepimut is an investigational immunotherapeutic vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and is a transforming oncogene that can directly contribute to cancer cell growth. Expression of EGFRvIII is linked to poor long term survival regardless of other factors such as extent of resection and age. EGFRvIII is expressed in approximately 30% of glioblastoma tumors. Celldex is actively enrolling two clinical studies of rindopepimut—a Phase 3 international study called ACT IV in patients with newly diagnosed EGFRvIII-positive glioblastoma and a Phase 2 study called ReACT in patients with recurrent EGFRvIII-positive glioblastoma. Dr. Mitchell has a patent that has been licensed by Celldex and may receive royalties related to sales of this immunotherapeutic vaccine.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs